Detail akcie Eli Lilly online

Business Summary: Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Eli Lilly And Co revenues increased 45% to $65.18B. Net income increased 95% to $20.64B. Revenues reflect Net product revenue increase of 50% to $60.96B. Net income benefited from Asset Impairment, Restructuring, and decrease of 44% to $484M (expense), Acquired in-Process Research and Deve decrease of 11% to $2.91B (expense). Dividend per share increased from $5.20 to $6.00.